NASDAQ:OMCLOmnicell Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Omnicell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $68.59 +0.55 (+0.81 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$67.30Now: $68.59▼$68.6050-Day Range$63.15MA: $67.66▼$72.6552-Week Range$54.24Now: $68.59▼$94.85Volume168,577 shsAverage Volume274,197 shsMarket Capitalization$2.93 billionP/E Ratio60.70Dividend YieldN/ABeta1.01 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Omnicell, Inc. provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides automated dispensing cabinets for medications and supplies used in nursing units, operating rooms, and emergency departments; analytics software to monitor drug diversion and address inventory management issues; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems used in hospitals and retail pharmacies for handling the stocking and retrieval of boxed medications. The Medication Adherence segment provides medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings; automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; and semi-automated filling equipment for the long-term care institutional pharmacy. It also offers Omnicell Patient Engagement, a subscription-based software system; patient communication tools, such as interactive voice response for pharmacies; and electronic Medication Administration Record software for use in nursing homes. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingOmnicell has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $85.50, Omnicell has a potential upside of 24.7% from its current price of $68.59.Amount of Analyst CoverageOmnicell has only been the subject of 4 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesOmnicell has received 456 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOmnicell has received 356 “underperform” votes. (Add your “underperform” vote.)Community SentimentOmnicell has received 56.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote “Outperform” if you believe OMCL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOmnicell does not currently pay a dividend.Dividend GrowthOmnicell does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Omnicell insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $423,270.00 in company stock.Percentage Held by InsidersOnly 2.63% of the stock of Omnicell is held by insiders.Percentage Held by Institutions95.79% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Omnicell are expected to grow by 40.85% in the coming year, from $1.42 to $2.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omnicell is 60.70, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.36.Price to Earnings Ratio vs. SectorThe P/E ratio of Omnicell is 60.70, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 32.88.Price to Earnings Growth RatioOmnicell has a PEG Ratio of 3.20. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioOmnicell has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.60 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electronic computers Sub-IndustryHealth Care Technology SectorMedical Current SymbolNASDAQ:OMCL Previous Symbol CUSIP68213N10 CIK926326 Webwww.omnicell.com Phone650-251-6100Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.48Price-To-Earnings Trailing P/E Ratio60.70 Forward P/E Ratio48.30 P/E Growth3.19 Sales & Book Value Annual Sales$897.03 million Price / Sales3.27 Cash Flow$3.85 per share Price / Cash Flow17.82 Book Value$20.75 per share Price / Book3.31Profitability EPS (Most Recent Fiscal Year)$2.19 Net Income$61.34 million Net Margins5.42% Return on Equity9.21% Return on Assets6.38%Miscellaneous Employees2,700 Outstanding Shares42,760,000Market Cap$2.93 billion Next Earnings Date10/22/2020 (Estimated) OptionableOptionable $68.59 +0.55 (+0.81 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive OMCL News and Ratings via Email Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter. Omnicell (NASDAQ:OMCL) Frequently Asked Questions How has Omnicell's stock been impacted by COVID-19 (Coronavirus)? Omnicell's stock was trading at $77.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OMCL shares have decreased by 11.4% and is now trading at $68.59. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Omnicell? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Omnicell. When is Omnicell's next earnings date? Omnicell is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020. View our earnings forecast for Omnicell. How were Omnicell's earnings last quarter? Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings results on Tuesday, July, 28th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.14. The business earned $199.62 million during the quarter, compared to analyst estimates of $182.16 million. Omnicell had a net margin of 5.42% and a return on equity of 9.21%. Omnicell's quarterly revenue was down 8.2% on a year-over-year basis. During the same period last year, the business posted $0.67 EPS. View Omnicell's earnings history. What guidance has Omnicell issued on next quarter's earnings? Omnicell issued an update on its third quarter earnings guidance on Tuesday, July, 28th. The company provided earnings per share (EPS) guidance of $0.44-0.52 for the period, compared to the Thomson Reuters consensus estimate of $0.55. The company issued revenue guidance of $204-212 million, compared to the consensus revenue estimate of $210.78 million. What price target have analysts set for OMCL? 8 Wall Street analysts have issued twelve-month target prices for Omnicell's stock. Their forecasts range from $70.00 to $100.00. On average, they anticipate Omnicell's stock price to reach $85.50 in the next twelve months. This suggests a possible upside of 24.7% from the stock's current price. View analysts' price targets for Omnicell. Has Omnicell been receiving favorable news coverage? Media coverage about OMCL stock has trended very positive recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Omnicell earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Omnicell. Who are some of Omnicell's key competitors? Some companies that are related to Omnicell include Cerner (CERN), HMS (HMSY), Allscripts Healthcare Solutions (MDRX), Cortexyme (CRTX), Vocera Communications (VCRA), HealthStream (HSTM) and Computer Programs & Systems (CPSI). View all competitors. What other stocks do shareholders of Omnicell own? Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Adobe (ADBE), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA) and Applied Materials (AMAT). Who are Omnicell's key executives? Omnicell's management team includes the following people: Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 62)Mr. Peter J. Kuipers, Exec. VP & CFO (Age 47)Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 55)Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 59)Mr. Nhat H. Ngo, Exec. VP of Marketing, Strategy & Bus. Devel. (Age 46) What is Omnicell's stock symbol? Omnicell trades on the NASDAQ under the ticker symbol "OMCL." Who are Omnicell's major shareholders? Omnicell's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Conestoga Capital Advisors LLC (3.53%), Principal Financial Group Inc. (0.76%), Paradigm Capital Management Inc. NY (0.75%), Tributary Capital Management LLC (0.75%), Peregrine Capital Management LLC (0.68%) and Scout Investments Inc. (0.58%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Scott Peter Seidelmann. View institutional ownership trends for Omnicell. Which institutional investors are selling Omnicell stock? OMCL stock was sold by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, Tygh Capital Management Inc., Oak Ridge Investments LLC, Redwood Investments LLC, Russell Investments Group Ltd., New York State Common Retirement Fund, Summit Creek Advisors LLC, and Ziegler Capital Management LLC. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Joanne B Bauer, Peter J Kuipers, Randall A Lipps, and Scott Peter Seidelmann. View insider buying and selling activity for Omnicell. Which institutional investors are buying Omnicell stock? OMCL stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., Trillium Asset Management LLC, Tributary Capital Management LLC, Vident Investment Advisory LLC, Vident Investment Advisory LLC, Raymond James & Associates, Pembroke Management LTD, and Hunter Perkins Capital Management LLC. View insider buying and selling activity for Omnicell. How do I buy shares of Omnicell? Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Omnicell's stock price today? One share of OMCL stock can currently be purchased for approximately $68.59. How big of a company is Omnicell? Omnicell has a market capitalization of $2.93 billion and generates $897.03 million in revenue each year. The company earns $61.34 million in net income (profit) each year or $2.19 on an earnings per share basis. Omnicell employs 2,700 workers across the globe. What is Omnicell's official website? The official website for Omnicell is www.omnicell.com. How can I contact Omnicell? Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
